Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,474 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,543 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05886491 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 16 | TakedaINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | terminated | Phase 1 / Phase 2 | 95 | TakedaINDUSTRY | 4 | Sep 24, 2026 | clinicaltrials |
| NCT05384119 |
| Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer |
| terminated |
| Phase 1 |
| 6 |
| Tvardi Therapeutics, IncorporatedINDUSTRY |
| 1 |
| Sep 24, 2026 |
| clinicaltrials |
| NCT06714591 | Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | terminated | Phase 1 | 52 | SystImmune Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas | terminated | Phase 1 | 14 | Boehringer IngelheimINDUSTRY | 3 | Sep 24, 2026 | clinicaltrials |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 3 | SystImmune Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03891615 | Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer | terminated | Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04601584 | GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL | terminated | Phase 1 / Phase 2 | 14 | AO GENERIUMINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04615845 | A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC | terminated | Phase 1 | 3 | Pharmicell Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04021368 | RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | terminated | Phase 1 | 51 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT04614051 | A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian Cancer | terminated | Phase 1 | 2 | Pharmicell Co., Ltd.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT01947140 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies(PDX+Romi) | terminated | Phase 1 / Phase 2 | 57 | Jennifer AmengualOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05316688 | A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery | terminated | Phase 1 / Phase 2 | 8 | University of WashingtonOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03634267 | MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer | terminated | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 62 | Hoffmann-La RocheINDUSTRY | 6 | Sep 15, 2026 | clinicaltrials |
| NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05014139 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | terminated | Phase 1 | 37 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Sep 14, 2026 | clinicaltrials |
| NCT04993391 | AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 32 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | terminated | Phase 1 / Phase 2 | 2 | BlueSphere Bio, IncINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04315233 | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics(CHARGE) | terminated | Phase 1 | 12 | University of UtahOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05275868 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 1 | 41 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT03145857 | A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use | terminated | Phase 1 / Phase 2 | 634 | AHS Cancer Control AlbertaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05813327 | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | terminated | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07076550 | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma | terminated | Phase 1 | 5 | Alpha-9 Oncology USA Inc.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06091930 | A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 | terminated | Phase 1 | 21 | Boehringer IngelheimINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04631601 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 55 | AmgenINDUSTRY | 6 | Aug 26, 2026 | clinicaltrials |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | terminated | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03184753 | Genetically Modified T Cells Against Ovarian Cancer | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03185468 | Intervention of Bladder Cancer by CAR-T | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03356795 | Intervention of CAR-T Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03362606 | Engineered Immune Effectors Against Ovarian Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03362619 | Engineered Immune Effectors Against Cervical Cancer | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04010877 | Multiple CAR-T Cell Therapy Targeting AML | terminated | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | terminated | Phase 1 / Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05262673 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL | terminated | Phase 1 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05277753 | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL | terminated | Phase 1 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04473781 | Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer | terminated | Phase 1 | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05497336 | A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer | terminated | Phase 1 | 8 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE) | terminated | Phase 1 | 85 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07408089 | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer(KOMODO-1) | terminated | Phase 1 | 8 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 2 | T-ACE Medical Co., LtdINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 97 | NextCure, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05101213 | Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | terminated | Phase 1 | 45 | Nuvectis Pharma, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials